Nektar Therapeutics (NKTR) Current Leases (2011 - 2026)

Nektar Therapeutics' Current Leases history runs 14 years deep, the most recent figure standing at $22.5 million for Q1 2026.

• In Q1 2026, Current Leases rose 3.15% year-over-year to $22.5 million; the TTM figure through Mar 2026 stood at $22.5 million (up 3.15% YoY), while the FY2025 annual figure was $20.5 million, up 3.16% from the prior year.
• Current Leases was $22.5 million for Q1 2026 at Nektar Therapeutics, up from $20.5 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $22.5 million in Q1 2026 to a low of $18.5 million in Q3 2022.
• Historically, Current Leases has averaged $20.2 million across 5 years, with a median of $19.9 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Current Leases climbed 24.28% in 2022, then dropped 5.56% in 2023.
• A 5-year view of Current Leases shows it stood at $18.7 million in 2022, then climbed by 3.17% to $19.3 million in 2023, then increased by 3.16% to $19.9 million in 2024, then climbed by 3.16% to $20.5 million in 2025, then advanced by 9.93% to $22.5 million in 2026.
• The last three Current Leases figures came in at $22.5 million (Q1 2026), $20.5 million (Q4 2025), and $22.2 million (Q3 2025), per Business Quant data.